Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - March 24, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 103     Next >>     Go To Page:

3/17/17 - Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed Products
Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada. MainPointe is an emerging OTC pharmaceutical company that brings added leverage to our NEXAFED business, commented Bob Jones, Ac
3/17/17 - Modernizing Medicine and Galderma Announce Integrated Over-the-Counter eCommerce Platform
By a News Reporter-Staff News Editor at Health& Medicine Week Specialty-specific health information technology leader Modernizing Medicine, Inc. and global leader in skin health, Galderma Laboratories, L.P., announced a collaboration to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider...
3/17/17 - Patent Issued for Dosage Form for Insertion into the Mouth (USPTO 9579295)
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Ryoo, Je Phil; Chu, Chun Kwong; Wang, Zheng, filed on July 20, 2015, was published online on February 28, 2017. The patent's assignee for patent number 9579295 is NAL PHARMACEUTICAL GROUP LIMITED. Migraine headache
3/16/17 - Congressman Serrano Introduces Bill to Require that Over-the-Counter Medicines are Packaged with Dosage Devices
Washington, DC- Congressman Jose E. Serrano today introduced the Protecting Our Kids Act of 2017, which would direct the Food and Drug Administration to require pharmaceutical companies to include dosage delivery devices, commonly known as flow restrictors, when selling over-the-counter medicines. This legislation will help keep our children safe b
3/16/17 - Rep. Serrano Introduces Bill to Require that Over-the-Counter Medicines are Packaged with Dosage Devices
Jose E. Serrano, D- N.Y., issued the following news release:. Congressman Jose E. Serrano today introduced the Protecting Our Kids Act of 2017, which would direct the Food and Drug Administration to require pharmaceutical companies to include dosage delivery devices, commonly known as flow restrictors, when selling over-the-counter medicines.
3/16/17 - Sonoma Pharmaceuticals Announces Results from SebuDerm? Gel Study in Treatment of Seborrheic Dermatitis
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the results of a clinical study evaluating the impact of SebuDerm? gel in the treatment of mild to moderate facial and scalp seborrheic
3/15/17 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Focus Groups About Drug Products as...
All comments should be identified with the OMB control number 0910-0677. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 10 A63, 11601 Landsdown St., North Bethesda, MD 20852, PRAStaff@fd
3/15/17 - Drug war strategies not working
The war on drugs is a never-ending game of whack-a-mole. That has been the story since President Richard Nixon declared war on drugs in June 1971. Since 2011, the state of Alabama has restricted the over-the-counter sale of some cold medicines that can be broken down and used to make methamphetamine.
3/15/17 - Publication of Annual Report and Financial Results for the Year Ended December 31, 2016
Hutchison China MediTech Limited announced today that on Monday March 13, 2017, it filed its annual report on Form 20- F with the U.S. Securities and Exchange Commission. Target 2018 launch in China as the first approved treatment for third-line CRC patients; 8 drug candidates now in 30 active clinical trials around the world with four pivotal Phas
3/15/17 - TELIGENT, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Teligent, Inc. is a specialty generic pharmaceutical company. All references to " Teligent," the "Company," "we," "us," and "our" refer to Teligent, Inc. Our mission is to become a leader in the specialty generic pharmaceutical market. Under our own label, we currently market and sell generic topical and branded generic injectable pharmaceutical pr
3/14/17 - Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com
Nutra Pharma Corporation, a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin and Pet Pain-Away? in the over-the-counter pain management market, announced today that Stockguru.com will be releasing an interview with Nutra Pharma's CEO through their website. "I appreciate the oppor
3/14/17 - ORASURE TECHNOLOGIES INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
Statements below regarding future events or performance are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results could be quite different from those expressed or implied by the forward-looking statements. Factors that could affect results are discussed more fully under the Item
3/14/17 - Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma
Tetra Bio-Pharma Inc., announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US $5.5 billion. The total ocular..
3/13/17 - Approval from FDA pushes Frederick biotech company into commercial marketplace [The Frederick News-Post, Md.]
March 13 As the nationwide war on opioid addiction wages on, a Frederick- based electroceutical company may have brought one solution to the market. BioElectronics Corp., which operates out of the Frederick Innovative Technology Center Inc., recently received over-the-counter clearance from the Federal Drug Administration for its flagship product
3/13/17 - BioPharmX Society of Toxicology Poster Suggests Promise of BPX-01 as Topical Acne Therapy, Highlights Safety
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, will share scientific data at the 55 th Annual Meeting of the Society of Toxicology, which will suggest the company's novel topical gel BPX-01 delivers acne-fighting medication to the target area safely without systemic side effects.
3/13/17 - GNW-News: Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor (english)
Novartis Kisqali receives FDA approval as first-line treatment for HR+/ HER2- metastatic breast cancer in combination with any aromatase inhibitor. Novartis International AG/ Novartis Kisqali receives FDA approval as first-line. treatment for HR+/ HER2- metastatic breast cancer in combination with any aromatase inhibitor.
3/13/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 12457) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss safety issues associated with over-the-counter analgesic combination products used for upset stomach and hangover indications under the...
3/13/17 - Innovus Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update on Monday, March 6, 2017
By a News Reporter-Staff News Editor at Pharma Business Week Innovus Pharmaceuticals, Inc.,, announced that the Company will release its fourth quarter and full year 2016 financial results and provide a corporate update on Monday, March 6, 2017, after the close of the U.S. financial markets. About Innovus Pharmaceuticals, Inc. Headquartered in Sa
3/13/17 - Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
The US Food and Drug Administration has approved Kisqali in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer. "Kisqali is emblematic of the innovation that Novar
3/13/17 - OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network
The acquisition of Vitel is expected to transform OncBioMune into a revenue-generating international pharmaceutical company with a more diverse product line with a particularly deep reach throughout Mexico, Central and Latin America, and relationships across Europe and Asia. Vitel founder Manuel Cosme Odabachian, an expert in drug licensing,...
3/13/17 - ONCBIOMUNE PHARMACEUTICALS, INC FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Registrant's Certifying Accountant, Changes in C
Vitel is a revenue-stage Mexico- based pharmaceutical company that develops and commercializes specialty drugs in Mexico and other Latin American countries. To induce the Vitel Stockholders to enter into the Contribution Agreement and as a condition to close the transactions set forth in that agreement, the Company, the Vitel Stockholders, Dr. Head
3/13/17 - Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets
Use this report to:- Receive information concerning the dynamics and forecasts in the OTC drugs and dietary supplements market- Receive information pertaining to the major regional trends in the global OTC drugs and dietary supplements market- Identify the key initiatives and strategies to control regulatory and supply chain issues for market gro
3/13/17 - Perrigo Announces Leadership Changes
By a News Reporter-Staff News Editor at Pharma Business Week- Perrigo Company plc, a leading global provider of Quality Affordable Healthcare Products , announced that Ron Winowiecki, Senior Vice President, Business Finance, has been appointed acting Chief Financial Officer, effective immediately, following the resignation of Judy L. Brown, Exe
3/13/17 - Sunovion Submits Supplemental New Drug Application to FDA for Use of APTIOM (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children 4 Years of Age and Older
Sunovion Pharmaceuticals Inc. today announced that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration to expand the indication for its antiepileptic drug APTIOM to include use as monotherapy or adjunctive therapy for the treatment of partial-onset seizures in children four years of age and older.
3/12/17 - MMJ PhytoTech Ltd (ASX:MMJ) Satipharm Sales Update and Expansion of European Distribution Network
Perth, Australia, Mar 13, 2017 MMJ PhytoTech Limited is pleased to provide the following sales and operations update on its wholly-owned Switzerland- based subsidiary, Satipharm AG. Satipharm has secured Pharmaceutical Central Numbers for its 10 mg and 50 mg Gelpell-CBD Microgel Capsules, enabling both products to be sold in all pharmacies throug
Articles(s): 1 - 25 of 103     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415